Publication: Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
cris.virtual.author-orcid | 0000-0001-7512-513X | |
cris.virtual.author-orcid | 0000-0002-9404-7736 | |
cris.virtualsource.author-orcid | 9afdf9b4-257a-4736-90ba-96d18a782972 | |
cris.virtualsource.author-orcid | 86929eee-8f06-473c-9d09-2b6d7b04c082 | |
cris.virtualsource.author-orcid | 8f95a220-083e-49cf-b70c-791e63056989 | |
cris.virtualsource.author-orcid | 5772bb1f-51a9-4cd5-b763-e6c548f75535 | |
cris.virtualsource.author-orcid | 547a1198-2574-4601-aa8a-5a3b147c870e | |
cris.virtualsource.author-orcid | 5b02b156-9f93-421d-bb36-a588ac9faa13 | |
cris.virtualsource.author-orcid | d6aac6e7-756f-4c96-934a-890456825dd7 | |
cris.virtualsource.author-orcid | 89351f1b-c3b3-4ff0-af2f-033f39da3188 | |
cris.virtualsource.author-orcid | e3d9151a-ebe0-4fa6-9f4e-8afa41cb8127 | |
cris.virtualsource.author-orcid | e85f3902-6c21-4fe3-bda2-c9126ffc8e84 | |
cris.virtualsource.author-orcid | 51cae653-8b4a-40cb-801b-42fa96a2f797 | |
cris.virtualsource.author-orcid | fe07c5e4-6205-4094-aebe-374a3866a26e | |
datacite.rights | open.access | |
dc.contributor.author | Haas, Quentin | |
dc.contributor.author | Markov, Nikita | |
dc.contributor.author | Mürner, Lukas Dominic | |
dc.contributor.author | Rubino, Viviana | |
dc.contributor.author | Benjak, Andrej | |
dc.contributor.author | Haubitz, Monika | |
dc.contributor.author | Bärlocher, Gabriela Maria | |
dc.contributor.author | Ng, Kiu Yan Charlotte | |
dc.contributor.author | Münz, Christian | |
dc.contributor.author | Riether, Carsten | |
dc.contributor.author | Ochsenbein, Adrian | |
dc.contributor.author | Simon, Hans-Uwe | |
dc.contributor.author | von Gunten, Stephan | |
dc.date.accessioned | 2024-10-11T17:22:14Z | |
dc.date.available | 2024-10-11T17:22:14Z | |
dc.date.issued | 2022 | |
dc.description.abstract | While inhibitory Siglec receptors are known to regulate myeloid cells, less is known about their expression and function in lymphocytes subsets. Here we identified Siglec-7 as a glyco-immune checkpoint expressed on non-exhausted effector memory CD8+ T cells that exhibit high functional and metabolic capacities. Seahorse analysis revealed higher basal respiration and glycolysis levels of Siglec-7+ CD8+ T cells in steady state, and particularly upon activation. Siglec-7 polarization into the T cell immune synapse was dependent on sialoglycan interactions in trans and prevented actin polarization and effective T cell responses. Siglec-7 ligands were found to be expressed on both leukemic stem cells and acute myeloid leukemia (AML) cells suggesting the occurrence of glyco-immune checkpoints for Siglec-7+ CD8+ T cells, which were found in patients' peripheral blood and bone marrow. Our findings project Siglec-7 as a glyco-immune checkpoint and therapeutic target for T cell-driven disorders and cancer. | |
dc.description.sponsorship | Institut für Pharmakologie | |
dc.description.sponsorship | Department for BioMedical Research (DBMR) | |
dc.description.sponsorship | Universitätsklinik für Medizinische Onkologie | |
dc.description.sponsorship | Department for BioMedical Research, Forschungsgruppe Tumor-Immunologie | |
dc.identifier.doi | 10.48350/173646 | |
dc.identifier.pmid | 36211376 | |
dc.identifier.publisherDOI | 10.3389/fimmu.2022.996746 | |
dc.identifier.uri | https://boris-portal.unibe.ch/handle/20.500.12422/88008 | |
dc.language.iso | en | |
dc.publisher | Frontiers Research Foundation | |
dc.relation.ispartof | Frontiers in immunology | |
dc.relation.issn | 1664-3224 | |
dc.relation.organization | DCD5A442BD11E17DE0405C82790C4DE2 | |
dc.relation.organization | DCD5A442BD18E17DE0405C82790C4DE2 | |
dc.relation.organization | DCD5A442C2CBE17DE0405C82790C4DE2 | |
dc.relation.organization | DCD5A442C3DBE17DE0405C82790C4DE2 | |
dc.relation.organization | DCD5A442C448E17DE0405C82790C4DE2 | |
dc.relation.organization | FE9070E90049439CAFD7E6B2FE6653E3 | |
dc.relation.organization | 5EBDFFD4994748B4B44FD17D5E463CFB | |
dc.relation.school | DCD5A442C27BE17DE0405C82790C4DE2 | |
dc.subject | CD8+ T cells Siglec-7 acute myeloid leukemia hypersialylation immune checkpoint sialoglycans tumor immunity and immunotherapy | |
dc.subject.ddc | 600 - Technology::610 - Medicine & health | |
dc.title | Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities. | |
dc.type | article | |
dspace.entity.type | Publication | |
dspace.file.type | text | |
oaire.citation.startPage | 996746 | |
oaire.citation.volume | 13 | |
oairecerif.author.affiliation | Institut für Pharmakologie | |
oairecerif.author.affiliation | Institut für Pharmakologie | |
oairecerif.author.affiliation | Institut für Pharmakologie | |
oairecerif.author.affiliation | Department for BioMedical Research, Forschungsgruppe Tumor-Immunologie | |
oairecerif.author.affiliation | Department for BioMedical Research (DBMR) | |
oairecerif.author.affiliation | Department for BioMedical Research (DBMR) | |
oairecerif.author.affiliation | Department for BioMedical Research (DBMR) | |
oairecerif.author.affiliation | Department for BioMedical Research (DBMR) | |
oairecerif.author.affiliation | Universitätsklinik für Medizinische Onkologie | |
oairecerif.author.affiliation | Universitätsklinik für Medizinische Onkologie | |
oairecerif.author.affiliation | Institut für Pharmakologie | |
oairecerif.author.affiliation | Institut für Pharmakologie | |
oairecerif.author.affiliation2 | Universitätsklinik für Medizinische Onkologie | |
oairecerif.author.affiliation2 | Department for BioMedical Research, Forschungsgruppe Hämatologie (Erwachsene) | |
oairecerif.author.affiliation2 | Department for BioMedical Research, Forschungsgruppe Hämatologie (Erwachsene) | |
oairecerif.author.affiliation2 | Department for BioMedical Research, Forschungsgruppe Tumor-Immunologie | |
oairecerif.author.affiliation2 | Department for BioMedical Research, Forschungsgruppe Tumor-Immunologie | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.date.licenseChanged | 2022-10-11 08:50:34 | |
unibe.description.ispublished | pub | |
unibe.eprints.legacyId | 173646 | |
unibe.journal.abbrevTitle | Front Immunol | |
unibe.refereed | true | |
unibe.subtype.article | journal |
Files
Original bundle
1 - 1 of 1
- Name:
- fimmu-13-996746.pdf
- Size:
- 7.8 MB
- Format:
- Adobe Portable Document Format
- File Type:
- text
- License:
- https://creativecommons.org/licenses/by/4.0
- Content:
- published